Eindhoven, The Netherlands-based Microsure plans to use the funds to finalize the development of its newest microsurgical robot. It intends to progress its MUSA-3 robot through clinical studies, then subsequent FDA clearance and CE mark approval.
The company designed MUSA-3 to “revolutionize the field of open microsurgery,” according to a news release. It offers surgeons precision, stability and control beyond human capabilities, the company says. The system builds upon its previous generations — the MUSA-2 robot.
MUSA-3 offers enhanced dexterity, a wider workspace and tremor reduction for enhanced precision. It integrates seamlessly with surgeons’ existing preferred micro-instruments from different brands. The system’s adaptability also enables its uses in a wide range of surgical procedures.
Microsure says its robot combines surgeon comfort with improved ergonomics. It enables surgeons to work from a console with digital exoscopes or hybrid surgical microscopes.
Details of the Microsure funding round
New investors, including the European Innovation Council Fund, Kineo, Invest-NL and other private groups joined in this round. Key existing shareholders, including Innovation Industries, BOM Ventures, Ten Cate Investerings Maatschappij, Venturing Tech, Eindhoven University of Technology and Microsure founders also participated.
In addition to the funding, Microsure also received an EIC Accelerator grant and an Innovation Loan from RvO, a division of the Dutch Ministry of Economic Affairs. The company also entered into an asset financing agreement with Kineo. That enables the company to offer appealing leasing options to hospitals adopting MUSA-3.
Microsure said the financing not only solidifies its financial foundation but reflects investor confidence in its technology. As part of the round, Kreske Nickelsen of Kineo joins the company’s supervisory board.
CEO Sjaak Deckers says the financing allows the company to advance its “groundbreaking technology.” Deckers extended gratitude to new and existing investors whose support “propelled Microsure to new heights.”
“The tireless efforts of the Microsure team over the past years have culminated in the development of a truly unique robot celebrated for its precision, ergonomic design, and adaptability for a wide spectrum of intricate procedures,” Deckers said. “Our progress is a testament to the exceptional talent within our growing team of dedicated individuals and the seamless collaboration with our key development and manufacturing partners.
“The continued expansion of Microsure’s clinical network strategically positions the company for upcoming clinical studies, an integral part of our journey towards securing FDA clearance and CE-mark certification.”
